Bisphosphonates in the treatment of malignant bone disease

Annual Review of Medicine

Volumn 50, Issue , 1999, Pages 237-248

  Berenson, James R ^a   Lipton, Allan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Bone metastases; Breast cancer; Multiple myeloma

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; MELPHALAN; PAMIDRONIC ACID; PREDNISOLONE;

BONE CANCER; BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCALCEMIA; MULTIPLE MYELOMA; OSTEITIS DEFORMANS; OSTEOCLASTS; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0032976794     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.50.1.237     Document Type: Review

References (38)

1. 1. Body JJ. 1998. Bisphosphonates. Eur. J. Cancer 34:263-69
2. 2. Lin JH. 1996. Bisphosphonates. A review of their pharmacokinetic properties. Bone 18:75-85
3. 3. Stashenko P, Dewhirst FE, Peros WJ, et al. 1987. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J. Immunol. 138:1464-68
4. 4. Mundy GR. 1991. Mechanisms of osteolytic bone destruction. Bone 12:1-6
5. 5. Belch AR, Bergsagel DE, Wilson K, et al. 1991. Effect of daily etidronate on the osteolysis of multiple myeloma. J. Clin. Oncol. 9:1397-1402
6. 6. Kyle RA, Jowsey J, Kelly PJ, Taves DR. 1975. Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N. Engl. J. Med. 293:1334-38
7. 7. Man Z, Otero AB, Rendo P, et al. 1990. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 335:663
8. 8. Thiebaud D, Leyuraz S, Von Fliedner V, et al. 1991. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur. J. Cancer 27:37-41
9. 9. Purohit OP, Anthony C, Radstone CR, et al. 1994. High-dose intravenous pamidronate for metastatic bone pain. Br. J. Cancer 70:554-58
10. 10. Berenson J, Lichtenstein A, Porter L, et al. 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334:488-93
11. 11. Lahtinen R, Laakso M, Palva I, et al. 1992. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049-52
12. 12. Heim ME, Clemens MR, Queisser W, et al. 1995. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie 18:439-48
13. 13. McCloskey EV, MacLennan ICM, Drayson MT, et al. 1998. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br. J. Haematol. 100:317-25
14. 14. Brincker H, Westin J, Abildgaard N, et al. 1998. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br. J. Haematol. 101:280-86
15. 15. Kellihan MJ, Mangino PD. 1992. Pamidronate. Ann. Pharmacother. 26:1262-69
16. 16. Berenson J, Lichtenstein A, Porter L, et al. 1998. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. 16:593-602
17. 17. Aparicio A, Gardner A, Tu Y, et al. 1998. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12:220-29
18. 18. Savage AD, Belson DJ, Vescio RA, et al. 1996. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 88:105a (Abstr.)
19. 19. Siris ES, Hyman GA, Canfield RE. 1983. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am. J. Med. 74:401-6
20. 20. Elomaa I, Blomqvist C, Grohn P, et al. 1983. Long-term controlled trial of bisphosphonate in patients with osteolytic bone metastases. Lancet 1:146-49
21. 21. Paterson AHG, Powles TJ, Kanis TA, et al. 1993. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:59-65
22. 22. Coleman RE, Woll PJ, Miles M, et al. 1988. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Br. J. Cancer 48:621-25
23. 23. Morton AR, Cantrill JA, Pillai GV, et al. 1988. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 297:772-73
24. 24. Burckhardt P, Thiebaud D, Percy L, von Fliedner V. 1989. Treatment of tumor-induced osteolysis by APD. Recent Result Cancer Res. 116:54-66
25. 25. Ette JW, Bijvoet OL, Cleton FJ, et al. 1986. Osteolytic bone metastases in breast carcinoma: pathogenesis, morbidity, and bisphosphonate treatment. Eur. J. Cancer Clin. Oncol. 22:493-500
26. 26. Van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, et al. 1991. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur. J. Cancer 27:544-49
27. 27. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. 1993. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:493-98
28. 28. Glover D, Lipton A, Keller A, et al. 1994. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose-seeking study. Cancer 74:2949-55
29. 29. Hortobagyi GN, Theriault RL, Porter L, et al. 1996. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335:1785-91
30. 30. Lipton A, Theriault R, Leff R, et al. 1997. Long term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy by monthly 90 mg pamidronate (Aredia) infusions. Proc. ASCO (May) 16 (Abstr. 531)
31. 31. Hortobagyi GN, Theriault RL, Lipton A, et al. 1998. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16:2038-44
32. 32. van der Pluijm G, Vloedgraven H, van Beek E, et al. 1996. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98:698-705
33. 33. Boissier S, Magnetto S, Frappart L, et al. 1997. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57:3890-94
34. 34. Sasaki A, Boyce BF, Story B, et al. 1995. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55:3551-57
35. 35. Conte PF, Latreille J, Maurik L, et al. 1996. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J. Clin. Oncol. 14:2552-59
36. 36. Kanis JA, Powles T, Paterson AHG, et al. 1996. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663-67
37. 37. Van Holten-Verzantvoort ATM, Hermans J, Beex LVAM, et al. 1996. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? Eur. J. Cancer 32A:450-54
38. 38. Diel IJ, Solomayer EF, Goerner R, et al. 1997. Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases. ASCO 16 (Abstr. 461)